Can I Take Resveratrol with Oral Estradiol?

Updated Jul 14, 2025

Image: HealthRX.com clinical illustration

At a glance

Drugs involved / resveratrol (a stilbene polyphenol supplement, not FDA-regulated as a drug) and oral estradiol (an FDA-approved estrogen tablet, brand name Estrace and generics, used for menopausal hormone therapy)
Interaction type / pharmacokinetic (enzyme inhibition affecting estradiol clearance) plus pharmacodynamic (resveratrol's own estrogen receptor activity)
Direct human trial data on the combination / none identified
Typical resveratrol supplement dose / commonly 100 to 500 mg per day; no FDA-approved dose exists because it is sold as a dietary supplement
Typical oral estradiol starting dose / 0.5 to 2 mg per day, per the FDA-approved label
What is established / resveratrol undergoes rapid, extensive first-pass metabolism and has weak estrogen receptor binding activity relative to estradiol
What is plausible but unproven / that supplement-level resveratrol doses meaningfully raise estradiol exposure in a person also taking oral estradiol tablets
What is not established / any measured change in serum estradiol, symptoms, or clinical outcomes when the two are combined
Bottom line / tell your prescriber you take resveratrol before starting or continuing oral estradiol, and expect a conversation about dose and monitoring rather than a flat "no"

Resveratrol is a polyphenol found in grape skins, red wine, and some berries, sold as an over-the-counter supplement (commonly 100 to 500 mg capsules) marketed for cardiovascular and longevity benefits. Oral estradiol is the FDA-approved bioidentical estrogen used in menopausal hormone therapy, taken as a swallowed tablet rather than a patch, gel, or vaginal preparation. The distinction between oral and non-oral estradiol matters here because oral dosing is the form most exposed to liver and gut first-pass metabolism, which is exactly where resveratrol's enzyme effects would matter most.

The core answer, and its limits

Resveratrol has documented, concentration-dependent inhibitory effects on CYP3A4 and glucuronidation enzymes in laboratory and small human pharmacokinetic studies, and it also binds estrogen receptors directly, making it a weak phytoestrogen. Both properties are mechanistically relevant to oral estradiol, which is cleared largely through CYP3A4 oxidation and glucuronide conjugation. No published clinical trial has measured serum estradiol concentrations in women taking oral estradiol and resveratrol together, so the practical size of this interaction in a real patient is not established; it is inferred from separate lines of evidence rather than demonstrated directly.

What resveratrol does to estradiol metabolism (the pharmacokinetic layer)

Oral estradiol is absorbed from the gut, passes through the intestinal wall and liver before reaching systemic circulation, and is metabolized primarily by CYP3A4 oxidation followed by glucuronidation (largely via UGT1A1) for excretion. This first-pass handling is why oral estradiol requires higher doses than transdermal or vaginal forms to achieve comparable blood levels.

Laboratory and small human pharmacokinetic studies of resveratrol have reported that it inhibits CYP3A4 and certain UGT enzymes at concentrations that can be reached in the gut wall after typical to high supplement doses, though resveratrol itself is rapidly and extensively conjugated (sulfated and glucuronidated) after absorption, which limits how much unmetabolized resveratrol reaches systemic circulation. The practical consequence, if any, would be more pronounced in the gut and liver during first-pass metabolism, which is the same site where oral estradiol is processed. This is a plausible mechanism, not a demonstrated clinical effect at ordinary supplement doses; the exact potency figures reported for resveratrol's enzyme inhibition vary across the pharmacology literature and should be verified against a specific primary source before being treated as a fixed number for any individual patient.

What resveratrol does on its own (the pharmacodynamic layer)

Separately from any effect on estradiol clearance, resveratrol binds estrogen receptors alpha and beta directly. Laboratory binding studies describe it as a much weaker agonist than estradiol itself, with a reported preference for ER-beta over ER-alpha in some assays, and describe its behavior as tissue-dependent, sometimes stimulating estrogen-responsive activity and sometimes acting as a partial antagonist depending on the cell type and concentration studied. This mixed behavior is the reason resveratrol is often classified alongside selective estrogen receptor modulators rather than as a simple estrogen mimic. The practical implication for someone on oral estradiol is straightforward even without knowing the exact binding numbers: resveratrol adds some estrogenic signal on top of a prescribed estrogen dose, and the size of that addition at typical supplement intakes is not well quantified in humans taking hormone therapy.

Evidence boundary: what is known, what is plausible, what is not established

Established:

Oral estradiol is metabolized substantially by CYP3A4 and glucuronidation, and the FDA label for oral estradiol warns that CYP3A4-inhibiting drugs as a class can raise circulating estrogen levels and side effects (verify exact label wording against the current label before quoting it).
Resveratrol binds estrogen receptors and has documented enzyme-inhibiting activity in laboratory and small human studies.
Resveratrol undergoes rapid first-pass conjugation, limiting how much reaches systemic circulation as the parent compound.

Plausible but unproven:

That resveratrol at common supplement doses (100 to 500 mg per day) meaningfully raises serum estradiol in someone taking oral estradiol tablets.
That the combination changes clinical outcomes (symptom control, breast or endometrial risk) compared with oral estradiol alone.

Not established:

Any published trial has directly measured serum estradiol, symptoms, or safety outcomes in women taking oral estradiol and resveratrol concurrently.
A specific "safe" resveratrol dose ceiling for someone on oral estradiol.

Does the resveratrol dose matter?

Direction, if not exact magnitude, is reasonably clear: enzyme inhibition and receptor occupancy are concentration-dependent processes, so higher resveratrol doses are more likely to matter than lower ones. Doses at the low end of what is commercially sold (roughly 50 to 150 mg per day, as found in many grape seed or polyphenol blends) are less likely to reach concentrations associated with meaningful enzyme inhibition than the higher end of dedicated resveratrol products (250 to 500 mg per day) or research-grade doses of 1 gram or more, which have been used in some human pharmacokinetic studies specifically because they are large enough to produce a measurable enzyme effect. This is a qualitative gradient, not a validated dosing rule for someone on oral estradiol, and it should not be used to select a "safe" supplement dose without a clinician's input.

Ordinary dietary exposure, such as a glass of red wine, delivers resveratrol in the low single-digit milligram range, well below any dose studied for enzyme or receptor effects, and is not a comparable exposure to a concentrated supplement capsule.

Who should be more cautious about this combination

Women with a history of estrogen receptor-positive breast cancer. Guideline bodies advise against exogenous estrogen exposure in this group; resveratrol's estrogen receptor agonist activity, however weak, places it in the same conversation, and any decision to use it should involve the treating oncology team.
Women taking oral estradiol without a progestogen and who still have a uterus. This is an atypical regimen, but if it applies to you, added estrogenic signaling from any source deserves closer endometrial monitoring because there is no progestogen counterbalance.
Women already near the upper end of the FDA-approved oral estradiol dose range. Less pharmacologic room exists before symptoms of excess estrogen exposure could appear.
Anyone taking a high-dose resveratrol product (gram-level doses) rather than a standard 100 to 500 mg supplement, since this is the range where human enzyme-inhibition data exists.

Possible benefits: what they do and do not tell us

Small randomized trials in postmenopausal women who were not taking hormone therapy have examined resveratrol for cardiovascular markers (such as flow-mediated dilation and lipid changes) and cognitive measures (such as verbal memory), with some reporting favorable results over placebo. These trials did not include women on oral estradiol, so they cannot tell you whether the effects are additive, redundant, or altered by concurrent hormone therapy. They are hypothesis-generating for future research, not a basis for combining resveratrol with oral estradiol to chase a specific benefit. Anyone relying on a specific study result from this body of research should verify it against the original trial publication rather than a secondary summary.

Does timing the doses apart help?

Not reliably. Resveratrol's active conjugated metabolites persist in tissue for several hours after the parent compound itself has cleared, so taking oral estradiol and resveratrol at different times of day narrows but does not eliminate the window during which both are present during first-pass metabolism. If a clinician is concerned about the interaction, adjusting the resveratrol dose or the estradiol dose, with monitoring, is a more dependable strategy than dose-spacing.

Evidence-status interaction assessment

Use this to frame the conversation with a prescriber or pharmacist rather than to self-manage the interaction.

Question	Status	What to do
Does the FDA oral estradiol label name resveratrol as an interaction?	Not established as a named interaction; the label's general class warning about CYP3A4 inhibitors is the closest relevant statement	Verify current label wording with your pharmacist; do not assume silence means "no interaction"
Can resveratrol inhibit enzymes that clear estradiol?	Established in laboratory and small human pharmacokinetic studies	Ask whether your estradiol dose and resveratrol dose together warrant a baseline and follow-up serum estradiol level
Does resveratrol bind estrogen receptors on its own?	Established, with weak affinity relative to estradiol	Consider it part of your total estrogenic exposure, especially if you have ER-positive breast cancer history or an intact uterus on unopposed estradiol
Has the combination been tested directly in a clinical trial?	Not established; no identified trial measured this pairing	Treat any specific numeric claim about combined effect size as unverified until you see the primary study
Does dose-timing separation solve the problem?	Not reliable, based on resveratrol's metabolite persistence	Discuss dose adjustment or monitoring instead of spacing doses
Is food-level resveratrol (wine, grapes) a concern?	Unlikely to be clinically meaningful given the much lower exposure	No specific action needed beyond general disclosure of diet and supplement use

What to bring to your prescriber

Bring the product label, not just the supplement name. Clinicians need the milligram dose per capsule and how many you take daily, because commercial resveratrol products vary widely in strength. Ask directly whether a baseline serum estradiol level, and a repeat level several weeks after starting or changing the resveratrol dose, makes sense for your regimen. If new breast tenderness, bloating, headache, unexpected bleeding, or mood changes appear after starting resveratrol, that is a reason to contact your prescriber promptly rather than wait for a routine visit; new or heavy uterine bleeding on hormone therapy warrants urgent evaluation regardless of the suspected cause.

If you switch or are considering switching to a transdermal or vaginal estradiol formulation, be aware that this reduces the first-pass pharmacokinetic concern (since less of the dose is exposed to gut and liver metabolism) but does not remove the separate question of resveratrol's own estrogen receptor activity, which applies across formulations.

Frequently asked questions

Can I take resveratrol while on oral estradiol?

It is not flagged as a specific contraindication on the oral estradiol label, but tell your prescriber before starting it. Resveratrol can inhibit enzymes that clear estradiol and also binds estrogen receptors directly, so the combination may increase your overall estrogenic exposure. No trial has measured this specific combination directly, so monitoring rather than a blanket rule is the practical approach.

Does resveratrol interact with oral estradiol?

A pharmacokinetic interaction (enzyme inhibition affecting estradiol clearance) and a pharmacodynamic interaction (resveratrol's own weak estrogen receptor activity) are both biologically plausible based on laboratory and small human studies. Neither has been directly measured in people taking oral estradiol and resveratrol together.

Is resveratrol a phytoestrogen?

Yes. It binds both estrogen receptor alpha and beta, generally with much weaker affinity than estradiol itself and a reported preference for ER-beta in some assays. Exact binding affinity figures vary across studies and should be checked against a specific primary source rather than treated as fixed.

Will resveratrol raise my estradiol blood level?

It might, based on its documented enzyme-inhibiting effects on CYP3A4 and glucuronidation, particularly at higher supplement doses. No published study has directly measured serum estradiol in women taking both oral estradiol and resveratrol, so this remains a plausible but unproven effect rather than a confirmed one.

What resveratrol dose is most likely to matter?

Higher doses are more likely to matter than lower ones, since enzyme inhibition is concentration-dependent. Standard dedicated resveratrol products (250 to 500 mg per day) are more plausible sources of concern than low-dose polyphenol blends (50 to 150 mg per day), and research-grade gram-level doses are where human enzyme-inhibition studies have most clearly shown an effect.

Is resveratrol safe for someone with a history of ER-positive breast cancer who is on oral estradiol?

Guideline bodies recommend against exogenous estrogen exposure for people with a personal history of ER-positive breast cancer. Resveratrol's estrogen receptor agonist activity, even though weak, means it should be discussed with the oncology team rather than started on your own.

Does spacing the doses apart prevent the interaction?

Not reliably. Resveratrol's active metabolites persist for several hours, so spacing doses narrows but does not remove the overlap during first-pass metabolism. A dose or monitoring adjustment discussed with your prescriber is more dependable than timing alone.

Do food sources of resveratrol, like red wine, carry the same concern?

Food-level resveratrol intake is far lower than a concentrated supplement capsule and is unlikely to produce a clinically meaningful enzyme or receptor effect, though this has not been specifically studied in people on oral estradiol.

Are transdermal or vaginal estradiol safer to combine with resveratrol?

Non-oral estradiol bypasses much of the liver and gut first-pass metabolism that oral estradiol undergoes, so the enzyme-inhibition concern from resveratrol is smaller with those forms. Resveratrol's direct estrogen receptor activity is not specific to a formulation and would still apply.

A note on the evidence in this article

Resveratrol's effects on drug-metabolizing enzymes and estrogen receptors are described across a body of laboratory and small human pharmacokinetic studies, and specific numeric findings (exact enzyme inhibition thresholds, binding affinity percentages, trial sample sizes) vary by source. This draft intentionally avoids citing specific PubMed identifiers because the underlying source material for this page could not be independently verified against the papers it named, and a mismatched citation is worse than none. Anyone relying on a precise number from this article for a clinical decision should ask their pharmacist or prescriber to pull the current primary literature rather than treat the figures above as fixed.

References

Natural Medicines Database (subscription clinical decision-support resource used by pharmacists for supplement-drug interaction lookups). https://naturalmedicines.therapeuticresearch.com

Additional claims about resveratrol pharmacokinetics, estrogen receptor binding, and clinical trial findings referenced in earlier drafts of this page require verification against their original primary publications before being restored with specific citations.